Group 1 - Company EnGene Biotech-B (09606.HK) plans to officially list on the Hong Kong Stock Exchange on April 15, having secured a prestigious lineup of cornerstone investors including BioNTech [1] - EnGene Biotech, established in 2019, focuses on developing antibody-drug conjugates (ADCs) aimed at treating cancer and autoimmune diseases, with two core products: DB-1303/BNT323 targeting HER2 for endometrial and breast cancer, and DB-1311/BNT324 targeting B7-H3 for small cell lung cancer, castration-resistant prostate cancer, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma [1] - The company also has five other ADCs in clinical stages and two bispecific ADCs (BsADCs) expected to enter clinical stages between 2025 and 2026, along with several preclinical ADCs [1] Group 2 - The company is offering a total of 15.0716 million shares globally, with 1.5072 million shares available in Hong Kong and 13.5644 million shares for international offering, plus a 15% over-allotment option [2] - The subscription period for the shares is from April 7 to April 10, 2025, with an expected share price range of HKD 94.60 to HKD 103.20, and assuming a price of HKD 98.90, the estimated net proceeds would be approximately HKD 1.3703 billion [2] - Cornerstone investors have committed to subscribe for a total of USD 65 million (approximately HKD 505.4 million) in shares, including major investors such as BioNTech and various healthcare-focused funds [3]
映恩生物今起招股 预计4月15日挂牌
Zheng Quan Shi Bao Wang·2025-04-07 00:17